Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Chafké Belmokhtar,Pierre Lozeron,David H. Adams,J. Franques,Arnaud Lacour,Etienne Godet,Mathieu Bataille,Odile Dubourg,Gilles Angibaud,Emilien Delmont,Françoise Bouhour,Philippe Corcia,Jean Pouget

Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

2019

Chafké Belmokhtar
Pierre Lozeron
David H. Adams
J. Franques
Arnaud Lacour
Etienne Godet
Mathieu Bataille
Odile Dubourg
Gilles Angibaud
Emilien Delmont
Françoise Bouhour
Philippe Corcia
Jean Pouget

Introduction Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a debilitating autoimmune neuropathy that is treated with intravenous immunoglobulin (IVIG). The aim of this retrospective study was to investigate the efficacy and safety of the sucrose-free IVIG Octagam® (Octapharma AG, Lachen, Switzerland) in patients with CIDP.

Keywords:

Gastroenterology
Immunotherapy
Octapharma
Polyradiculoneuropathy
Retrospective cohort study
Internal medicine
Medicine
Chronic inflammatory demyelinating polyneuropathy
Physical therapy
Neurology
Adverse drug reaction
Adverse effect
Prospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations